<DOC>
	<DOCNO>NCT02110368</DOCNO>
	<brief_summary>Bioequivalence study compare rate extent testosterone absorption test formulation versus reference product .</brief_summary>
	<brief_title>Bioequivalence Study Test Reference Testosterone Topical Gel , 1.62 % Metered Pump Testosterone Deficient Adult Male Subjects Under Fasting Conditions</brief_title>
	<detailed_description>To compare rate extent testosterone absorption test formulation Testosterone Topical Gel , 1.62 % Metered Pump , manufacture AndroGel速 ( testosterone gel ) 1.62 % Metered-Dose Pump , normal , healthy , adult , testosterone-deficient ( hypogonadal ) human male subject fast condition .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Healthy adult men hypogonadism testosterone level &lt; 250ng/dL 18 65 year age ( inclusive ) Have normal PSA &lt; 4.0ng/mL Weighing minimum 50 kg body mass index 18.0 38.0 kg/m2 . Good health determine medical history lack clinically significant abnormality ( hypogonadism ) . Vital sign , must within follow range heart rate : 45100 bpm ; systolic BP : 90150 mmHg ; diastolic BP : 5090 mmHg . Outofrange vital sign may repeat . Is female History allergy sensitivity AndroGel速 component drug relate testosterone drug , Axiron速 , Testim速 , etc . History allergy intolerance soy , soybean , and/or soy lecithin History drug food hypersensitivity intolerance , would compromise safety subject study . History presence clinically significant ocular , cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , oncologic , psychiatric disease othercondition , would jeopardize safety subject validity study result . Had major surgery illness within 3 month screen . History presence benign prostate hypertrophy , prostate and/or breast cancer . Has tattooed , damage , scar skin skin condition right leave upper arm shoulder region may affect absorption drug . Has clinically significant abnormal find physical exam , medical history , electrocardiogram clinical laboratory result screen . Has significantly abnormal diet 4 week precede first dose study medication . Has donate blood within 56 day plasma within 30 day prior first dose study medication . Has participate another clinical trial within 30 day prior first dose study medication . Has use overthecounter medication , include nutritional supplement , within 7 day prior first dose study medication . Has use prescription medication include hormonal treatment supplement within 30 day prior first dose study medication . No depot injection drug implant within 3 month first dose study medication . Has treat know drug moderate strong inhibitors/inducers CYP enzymes barbiturate , phenothiazine , cimetidine , carbamazepine , etc. , within 30 day prior first dose study medication may impact subject safety validity study result . Has positive cotinine test and/or smoke use tobacco product within 60 day prior first dose study medication Has positive urine screen drug abuse Has positive alcohol breathalyzer test Has positive test Hepatitis B surface antigen , Hepatitis C antibody , Human Immunodeficiency Virus ( HIV ) screen previously treat Hepatitis B , Hepatitis C , HIV infection . Any difficulty fast dietary restriction lactose intolerance , vegan , lowfat , etc . Unavailable confinement day schedule visit .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>